Dr. Sameh R. Gaballa, MD

Medicare patients and services

Medicare patients, 2024

147

Services billed

327

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 10 companies reported 44 payments worth $36,381 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $2,393,133 in research payments for these studies, mostly to the institutions running them.

• A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
  Kite Pharma, Inc.
• A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody Targeting CD19 in Subjects with relapsed or refractory B-Cell non HodGkin Lyphoma (TNB486.001)
  AstraZeneca Pharmaceuticals LP
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
  Epizyme, Inc. · Active, not recruiting · NCT04224493
• A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follic…
  E.r. Squibb & Sons, L.l.c.
• Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
  Beone Medicines USA, Inc. · Recruiting · NCT06350318
• A Modular Phase II, Single-arm, Multicenter, Open-label study to evaluate the Efficacy and Safety of AZD0486 in Subjects with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)
  AstraZeneca Pharmaceuticals LP
• CCT5065
  Adaptive Biotechnologies Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Tampa

• Mohammed A. Al-jumayli, M.D
• Yasir Alsaraf, MD
• Rand W. Altemose, M.D.
• Claudio Anasetti, MD
• Scott Antonia, MD
• Nelli Bejanyan, M.D.
• Tiago Biachi De Castria, MD PHD
• Rafael W. Blanco, M. D.